DDInter1702 DDInter734
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora. The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.
Sorafenib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Sorafenib {u} (Compound) downregulates {v} (Gene) DHX9
DHX9 {u} (Gene) interacts with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib {u} (Compound) upregulates {v} (Gene) HAX1
HAX1 {u} (Gene) interacts with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Fidaxomicin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Toremifene {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Sorafenib (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Fidaxomicin (Compound)
Sorafenib (Compound) downregulates DHX9 (Gene) and DHX9 (Gene) interacts with ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Sorafenib (Compound) upregulates HAX1 (Gene) and HAX1 (Gene) interacts with ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Fidaxomicin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Fidaxomicin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)